Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)
Status:
Terminated
Trial end date:
2018-02-04
Target enrollment:
Participant gender:
Summary
To describe the long-term safety of deforolimus (ridaforolimus, MK-8669) in participants for
whom a clinical benefit has been established in a prior parent trial (MK-8669-013,
NCT00060645; MK-8669-016, NCT00112372; and MK-8669-028, NCT00704054) with deforolimus and/or
in those who remain in long-term follow-up.